Identifying aggressive prostate cancer using biomarkers

Core-Biomarker Reference Laboratory

NIH-funded research Old Dominion University · NIH-10911314

This study is looking for ways to tell the difference between slow-growing and fast-growing prostate cancer by examining urine and tissue samples, so that patients can get better diagnoses and personalized treatment based on their specific cancer type.

Quick facts

Grant typeNIH-funded research
Study typeNIH-funded research
Funding institutionOld Dominion University NIH-funded
Lab location1 site (Norfolk, United States)
Project IDNIH-10911314 on NIH RePORTER

What this research studies

This research focuses on developing and validating biomarkers that can distinguish between indolent and aggressive forms of localized prostate cancer. By analyzing prostate proximal fluids and tumor tissues, the study aims to identify molecular features that indicate the risk of disease progression. The research will utilize urine-based and tissue-based assays to improve early detection and risk stratification for patients, particularly those with high-grade lesions or BRCA2 variants. Patients will benefit from more accurate diagnoses and tailored treatment options based on their specific cancer characteristics.

Who could benefit from this research

Good fit: Ideal candidates for this research are men who have been newly diagnosed with localized prostate cancer and are at risk for aggressive disease.

Not a fit: Patients with advanced prostate cancer or those who do not have localized disease may not benefit from this research.

Why it matters

Potential benefit: If successful, this research could lead to earlier and more accurate identification of aggressive prostate cancer, allowing for timely and appropriate treatment.

How similar studies have performed: Previous research has shown promise in using biomarkers for cancer detection, indicating that this approach has potential for success.

Where this research is happening

Norfolk, United States

Researchers

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions Breast Cancer 2 GeneBreast Cancer Type 2 Susceptibility Gene
Last reviewed 2026-06-09 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.